NCT01140542View on ClinicalTrials.gov

Efficacy of 500µg Roflumilast Once Daily Versus Placebo Over 12 Weeks in Patients With Diabetes Mellitus Type 2. A Double Blind, Parallel Group, Proof of Concept Clinical Study

PHASE2CompletedINTERVENTIONAL

Enrollment

487

Participants

Timeline

Start Date

August 31, 2006

Primary Completion Date

November 30, 2007

Study Completion Date

March 31, 2008

Conditions

Diabetes Mellitus Type 2

Interventions

DRUG

Roflumilast

500µg, once daily

Sponsors

Lead Sponsor

All Listed Sponsors

lead

AstraZeneca

INDUSTRY

NCT01140542 - Efficacy of 500µg Roflumilast Once Daily Versus Placebo Over 12 Weeks in Patients With Diabetes Mellitus Type 2. A Double Blind, Parallel Group, Proof of Concept Clinical Study | Biotech Hunter | Biotech Hunter